^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Melanoma |
| Drug: | Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor) + plixorafenib (FORE-8394) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
Published date:
08/25/2020
Excerpt:
BRAF V600E-mutated colorectal (WiDr, RKO, Colo 201, and LS411N) and melanoma (G361 and A375) cell lines were treated with each drug covering a 10,000-fold concentration range....PLX8394 demonstrated greater efficacy in two lines compared to encorafenib (Colo 201 P = 0.016 and RKO P = 0.002), with encorafenib showing superiority in one line (G361 P = 0.0311)...
DOI:
https://doi.org/10.18632/oncotarget.27681
